Task C3 · comparison
Compare CDK4/6 inhibitors and PARP inhibitors as described in the corpus: what breast/gynecological cancer contexts and mechanisms does each target?
Gold evidence
Acceptable answer concepts
- CDK4/6 inhibitors combined with endocrine therapy target hormone receptor-positive, HER2-negative breast cancer via the retinoblastoma pathway
- PARP inhibitors target homologous recombination deficiency (HRD) in ovarian and breast cancers
Construction note
PMID:42698831 (CDK4/6 inhibitors, HR+/HER2- breast cancer) and PMID:42648415 (PARP inhibitors, HRD ovarian/breast cancer) describe genuinely distinct biomarkers and mechanisms; a correct comparison must not merge them into one undifferentiated 'targeted therapy' claim.
How each architecture answered
Baseline 0 · no retrieval
Yuu no Sekai · 460 tokens · 3.1s(abstained) No evidence passages were retrieved to compare CDK4/6 inhibitors and PARP inhibitors in terms of breast/gynecological cancer contexts and mechanisms.
The comparison of CDK4/6 inhibitors and PARP inhibitors in breast/gynecological cancer contexts and mechanisms cannot be made without evidence.
Baseline 1 · retrieve + synthesize
Yuu no Sekai · 2827 tokens · 7.5sCDK4/6 inhibitors are primarily used in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, targeting mechanisms such as retinoblastoma-pathway escape and cyclin E-cyclin-dependent kinase 2 (CDK2) activation. PARP inhibitors are used in breast and ovarian cancers with homologous recombination deficiency (HRD), targeting DNA repair defects and mechanisms including synthetic lethality, PARP trapping, immune activation, and metabolic reprogramming.
CDK4/6 inhibitors are used in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
PARP inhibitors are used in ovarian and breast cancers with homologous recombination deficiency (HRD).
CDK4/6 inhibitors target mechanisms including retinoblastoma-pathway escape and cyclin E-cyclin-dependent kinase 2 (CDK2) activation.
PARP inhibitors target DNA repair defects and mechanisms including synthetic lethality, PARP trapping, immune activation, and metabolic reprogramming.
Agent 1 · planner + retrieve + synthesize
Yuu no Sekai · 3219 tokens · 10.2sCDK4/6 inhibitors are primarily used in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, targeting mechanisms such as retinoblastoma-pathway escape and phosphoinositide 3-kinase (PI3K)-AKT-mechanistic target of rapamycin (mTOR) signaling. PARP inhibitors are used in ovarian and breast cancers with homologous recombination deficiency (HRD), targeting mechanisms involving DNA repair defects and immune activation. Both have roles in gynecological cancers but through different mechanisms.
CDK4/6 inhibitors are used in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
CDK4/6 inhibitors target mechanisms such as retinoblastoma-pathway escape and phosphoinositide 3-kinase (PI3K)-AKT-mechanistic target of rapamycin (mTOR) signaling.
PARP inhibitors are used in ovarian and breast cancers with homologous recombination deficiency (HRD).
PARP inhibitors target mechanisms involving DNA repair defects and immune activation.
Both CDK4/6 inhibitors and PARP inhibitors have roles in gynecological cancers.